JP2021527712A5 - - Google Patents
Info
- Publication number
- JP2021527712A5 JP2021527712A5 JP2021519529A JP2021519529A JP2021527712A5 JP 2021527712 A5 JP2021527712 A5 JP 2021527712A5 JP 2021519529 A JP2021519529 A JP 2021519529A JP 2021519529 A JP2021519529 A JP 2021519529A JP 2021527712 A5 JP2021527712 A5 JP 2021527712A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- pabra
- blocker
- composition according
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685244P | 2018-06-14 | 2018-06-14 | |
| US62/685,244 | 2018-06-14 | ||
| US201862686654P | 2018-06-18 | 2018-06-18 | |
| US62/686,654 | 2018-06-18 | ||
| US201962825619P | 2019-03-28 | 2019-03-28 | |
| US62/825,619 | 2019-03-28 | ||
| PCT/US2019/037371 WO2019241744A1 (en) | 2018-06-14 | 2019-06-14 | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527712A JP2021527712A (ja) | 2021-10-14 |
| JPWO2019241744A5 JPWO2019241744A5 (https=) | 2022-06-08 |
| JP2021527712A5 true JP2021527712A5 (https=) | 2022-06-08 |
Family
ID=68842373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519529A Pending JP2021527712A (ja) | 2018-06-14 | 2019-06-14 | 神経系疾患および障害を、診断、監視、および治療するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210251559A1 (https=) |
| EP (1) | EP3806957A4 (https=) |
| JP (1) | JP2021527712A (https=) |
| AU (1) | AU2019287779A1 (https=) |
| CA (1) | CA3100697A1 (https=) |
| WO (1) | WO2019241744A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4076422A4 (en) * | 2019-12-18 | 2024-01-24 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| JP7734700B2 (ja) * | 2020-06-04 | 2025-09-05 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニストの形態及び組成物 |
| CN116801875A (zh) * | 2020-09-01 | 2023-09-22 | 库拉森疗法公司 | 用于改善神经疾病和病症的组合物和方法 |
| EP4208159A4 (en) * | 2020-09-01 | 2024-09-25 | Curasen Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE RELIEF OF NEUROLOGICAL CONDITIONS AND DISORDERS |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
| US9492114B2 (en) * | 2004-06-18 | 2016-11-15 | Banner Health Systems, Inc. | Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease |
| US8758723B2 (en) * | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| JP6133790B2 (ja) * | 2011-02-18 | 2017-05-24 | ザ スクリプス リサーチ インスティテュート | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
| US9320724B2 (en) * | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| WO2014152529A2 (en) * | 2013-03-14 | 2014-09-25 | Georgetown University | Fmri biomarker of neurodegenerative disease |
| US9889087B2 (en) * | 2014-06-10 | 2018-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor |
| WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
-
2019
- 2019-06-14 JP JP2021519529A patent/JP2021527712A/ja active Pending
- 2019-06-14 EP EP19819482.1A patent/EP3806957A4/en not_active Withdrawn
- 2019-06-14 AU AU2019287779A patent/AU2019287779A1/en not_active Abandoned
- 2019-06-14 US US16/972,985 patent/US20210251559A1/en not_active Abandoned
- 2019-06-14 WO PCT/US2019/037371 patent/WO2019241744A1/en not_active Ceased
- 2019-06-14 CA CA3100697A patent/CA3100697A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527712A5 (https=) | ||
| JP2021527711A5 (https=) | ||
| Chien et al. | Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808 | |
| KR101581289B1 (ko) | 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민 | |
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| JP2011093924A (ja) | （−）−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
| US20180092896A1 (en) | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with a-beta peptide aggregation | |
| JPWO2021127210A5 (https=) | ||
| JP2008520589A5 (https=) | ||
| JP2021505575A (ja) | 非ラセミ混合物およびその使用 | |
| AU2006264317B2 (en) | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders | |
| Hesse et al. | Is correction for age necessary in neuroimaging studies of the central serotonin transporter? | |
| JPWO2019241744A5 (https=) | ||
| Kang et al. | Investigating the effects of noise-induced hearing loss on serotonin transporters in rat brain using 4-[18F]-ADAM/small animal PET | |
| Ma et al. | Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography | |
| MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
| Battistin et al. | Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine | |
| JPWO2019241736A5 (https=) | ||
| Molchan et al. | A double FDG/PET study of the effects of scopolamine in older adults | |
| JP2018530612A5 (https=) | ||
| Schreckenberger et al. | ” Ecstasy”-induced changes of cerebral glucose metabolism and their correlation to acute psychopathology: An 18-FDG PET Study | |
| Kao et al. | Regional cerebral blood flow of Alzheimer's disease-like pattern in young patients with Down's syndrome detected by 99Tcm-HMPAO brain SPECT | |
| JP2012512251A (ja) | トリプル再取込み阻害剤及びそれらの使用方法 | |
| JP2019529502A5 (https=) | ||
| Ahn et al. | Preclinical evaluation of [18F] FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson’s disease: pharmacokinetic and efficacy analysis |